- Home
- NAAS vs HOOK Comparison
NAAS vs HOOK Comparison
Compare NAAS & HOOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAAS
- HOOK
- Stock Information
- Founded
- NAAS 2019
- HOOK 2011
- Country
- NAAS China
- HOOK United States
- Employees
- NAAS N/A
- HOOK N/A
- Industry
- NAAS Other Specialty Stores
- HOOK Biotechnology: Pharmaceutical Preparations
- Sector
- NAAS Consumer Discretionary
- HOOK Health Care
- Exchange
- NAAS Nasdaq
- HOOK Nasdaq
- Market Cap
- NAAS 8.3M
- HOOK 9.3M
- IPO Year
- NAAS 2017
- HOOK 2019
- Fundamental
- Price
- NAAS $1.23
- HOOK $1.30
- Analyst Decision
- NAAS
- HOOK Buy
- Analyst Count
- NAAS 0
- HOOK 4
- Target Price
- NAAS N/A
- HOOK $10.67
- AVG Volume (30 Days)
- NAAS 1.3M
- HOOK 139.6K
- Earning Date
- NAAS 05-20-2025
- HOOK 05-20-2025
- Dividend Yield
- NAAS N/A
- HOOK N/A
- EPS Growth
- NAAS N/A
- HOOK N/A
- EPS
- NAAS N/A
- HOOK N/A
- Revenue
- NAAS $43,258,393.00
- HOOK $43,946,000.00
- Revenue This Year
- NAAS $19.53
- HOOK N/A
- Revenue Next Year
- NAAS $151.36
- HOOK N/A
- P/E Ratio
- NAAS N/A
- HOOK N/A
- Revenue Growth
- NAAS 50.34
- HOOK 118.32
- 52 Week Low
- NAAS $1.23
- HOOK $0.72
- 52 Week High
- NAAS $76.80
- HOOK $10.50
- Technical
- Relative Strength Index (RSI)
- NAAS 27.23
- HOOK 58.05
- Support Level
- NAAS $1.18
- HOOK $1.14
- Resistance Level
- NAAS $3.49
- HOOK $1.67
- Average True Range (ATR)
- NAAS 0.28
- HOOK 0.17
- MACD
- NAAS 0.04
- HOOK 0.08
- Stochastic Oscillator
- NAAS 2.16
- HOOK 60.11
About NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators. wide range of offline services that simplify the daily operations of charging station operators, and of non-charging services such as food and beverage services to station operators.
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.